Pharmaceuticals, Biotechnology & Life Sciences

Cypherpunk Technologies sees major share purchase by Winklevoss family and CEO, boosting confidence in its biotech cancer therapy prospects.

Moderna shares climb as investors await Phase 3 melanoma trial results—could a breakthrough in personalized mRNA vaccines reshape oncology?

Discover how MannKind Corp’s participation in the Chardan Healthcare Conference is driving innovation in chronic respiratory disease therapies and investor engagement.

Amgen’s robust R&D pipeline and disciplined cash‑flow strategy position the company to thrive amid stagflation, AI‑driven drug discovery, and supply‑chain resilience, driving shareholder value and growth.

Amarin Corporation PLC hits a 52‑week low of €10 on the Frankfurt Exchange, revealing market volatility while it pursues breakthrough cardiovascular therapeutics.

ImmunityBio’s Phase 3 results show 84 % cystectomy avoidance for BCG‑unresponsive bladder cancer and durable complete responses beyond 53 months, boosting investor confidence.

Altimmune’s peptide‑based therapeutics aim to transform addiction treatment, targeting glutamatergic pathways for reduced cravings and sustained abstinence.

Regeneron’s Libtayo receives EMA approval for a streamlined 12‑week to 6‑week dosing schedule, boosting patient adherence and market competitiveness.

Alnylam faces analyst downgrades amid a surge of RNA‑i start‑ups; its Q3 webcast will decide if it can retain lofty valuation or cede ground to rivals.

Hyperliquid Strategies (HYPE) surges as Ripple Prime expands to RWA swaps & perpetual futures, while a $100 M stake boosts stability—see how institutional moves shape HYPE’s future.